Journal article icon

Journal article

Preclinical safety studies of enadenotucirev, a chimeric group B human-specific oncolytic adenovirus

Abstract:

Enadenotucirev is an oncolytic group B adenovirus identified by a process of bio-selection for the ability to selectively propagate in and rapidly kill carcinoma cells. It is resistant to inactivation by human blood components, potentially enabling intravenous dosing in patients with metastatic cancer. However, there are no known permissive animal models described for group B adenoviruses that could facilitate a conventional approach to preclinical safety studies. In this manuscript, we descr...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1016/j.omto.2017.03.003

Authors


More by this author
Department:
Oxford, MSD, Oncology
Role:
Author
More by this author
Department:
Oxford, MSD, Oncology
Role:
Author
More by this author
Department:
Oxford, MSD, Oncology
Role:
Author
Expand authors...
PsiOxus Therapeutics More from this funder
Publisher:
Elsevier Publisher's website
Journal:
Molecular Therapy - Oncolytics Journal website
Volume:
5
Pages:
62-75
Publication date:
2017-03-29
Acceptance date:
2017-03-18
DOI:
ISSN:
2372-7705
Pubs id:
pubs:695851
URN:
uri:bcaf476b-54f6-414a-a9c4-edfb703f84dd
UUID:
uuid:bcaf476b-54f6-414a-a9c4-edfb703f84dd
Local pid:
pubs:695851

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP